Loading
companiesCompany
Deciphera Pharmaceuticals (Ono)
Kinase-switch-control company behind ripretinib for GIST and vimseltinib for tenosynovial giant cell tumour; bought by Ono Pharmaceutical in 2024.
Overview
Deciphera Pharmaceuticals, based in Waltham, Massachusetts, is the kinase-switch-control company behind ripretinib for gastrointestinal stromal tumour and vimseltinib for tenosynovial giant cell tumour, and it was bought by Ono Pharmaceutical in 2024 for around 2.4 billion dollars. Ripretinib, sold as Qinlock, was approved in 2020 on the INVICTUS trial, with INTRIGUE and INSIGHT following, and vimseltinib, sold as Romvimza, was approved on 14 February 2025 on the MOTION trial. OnCo links it to GIST, soft tissue sarcomas and tenosynovial giant cell tumour, and to both drug records. Whether switch-control inhibition yields further drugs beyond these two rare indications is the open question now that it sits inside a Japanese pharma. Ripretinib and vimseltinib have their own pages.
Headquarters
Waltham, MA, US
Scorecard
All companies#185of 1244 companies, score 31
- approved products +12
- phase 1/2 +1
- targets +2
- modalities +2
- regions +5
- 24-month regulatory events +2
- registry trials +7
2 approved, 0 in phase 3, 1 earlier, 1 targets, 12 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-04-29 | Deciphera Pharmaceuticals (Ono) to Ono Pharmaceutical Ripretinib (Qinlock) and vimseltinib | Acquisition | not disclosed | $2.4bn | source |
Type
Website
ApprovedSmall-molecule kinase inhibitor (KIT/PDGFRA switch-control)
Ripretinib · Qinlock
A fourth-line GIST drug that locks KIT in an off state regardless of which resistance mutation the tumour has acquired.
ApprovedSmall-molecule kinase inhibitor (CSF1R)
Vimseltinib · Romvimza
Vimseltinib is a pill approved in February 2025 for tenosynovial giant cell tumour, a benign but destructive joint tumour, offering an alternative to repeated surgery.
Phase 2Oral serine/threonine kinase inhibitor
Inlexisertib is an oral serine/threonine kinase inhibitor from Deciphera Pharmaceuticals, LLC, in registered phase 2 trials for metastatic cancer.
Similar pages
- TargetDCC
Shares A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST), A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies, Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor.
- CancerImatinib-resistant GIST
Shares A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib, INVICTUS, INSIGHT, Ripretinib.
- PairingctDNA KIT genotyping → TKI selection in GIST
Shares INSIGHT, Ripretinib, Sarcomas (soft tissue, bone, GIST).
- Key paperINVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors
Shares INVICTUS, Ripretinib.
- TargetCSF1
- TargetKIT
Shares INVICTUS, INSIGHT, Ripretinib, Gastrointestinal stromal tumour (GIST).
- CancerKIT exon 11-mutant GIST
Shares INSIGHT, Ripretinib, Gastrointestinal stromal tumour (GIST).
- TargetCSF1R
Shares Vimseltinib, Tenosynovial giant cell tumour (TGCT), Sarcomas (soft tissue, bone, GIST).
cancers
fronts
drugs
Phase 2Oral serine/threonine kinase inhibitor
ApprovedSmall-molecule kinase inhibitor (KIT/PDGFRA switch-control)
Ripretinib · Qinlock
ApprovedSmall-molecule kinase inhibitor (CSF1R)
Vimseltinib · Romvimza
trials
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesA Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)INSIGHTINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)INVICTUSMOTIONStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerStudy of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor